Global Heart Failure Therapeutics Market Size By Type (Diagnosis, Prognosis), By Application (Hospital, Clinic), By Region, And Segment Forecasts, 2023 to 2032

The Global Heart Failure Therapeutics Market was valued at USD 13.6 billion in 2023 and is projected to reach USD 24.8 billion by 2031, growing at a CAGR of 7.8% during the forecast period from 2023 to 2031. The increasing prevalence of cardiovascular diseases, aging populations, and rising demand for advanced heart failure treatment options are key factors driving market growth. Advancements in biologics, gene therapy, and drug-device combination therapies are further expanding the therapeutic landscape. Public and private investments in cardiac care infrastructure and heightened awareness about early diagnosis are also supporting market expansion globally.

Drivers

1. Rising Prevalence of Heart Failure:

Heart failure remains a leading cause of hospitalization and mortality worldwide. The increasing incidence of hypertension, diabetes, and coronary artery disease significantly contributes to heart failure cases, thereby increasing the demand for effective therapeutics.

2. Advancements in Therapeutic Modalities:

The introduction of novel drug classes such as angiotensin receptor-neprilysin inhibitors (ARNIs), SGLT2 inhibitors, and gene therapies is transforming heart failure management, improving patient outcomes and extending survival rates.

3. Aging Global Population:

The risk of heart failure escalates with age. As the global geriatric population continues to rise, so does the patient base requiring chronic heart failure management, thereby fueling demand for long-term therapeutic solutions.

Restraints

1. High Cost of Treatment:

Innovative heart failure therapies, especially biologics and implantable devices, come with high costs, posing affordability challenges in low and middle-income regions and potentially limiting patient access.

2. Side Effects and Non-Adherence:

Many heart failure drugs have significant side effects, leading to poor patient adherence. Long-term medication regimens also face compliance issues, affecting treatment efficacy and outcomes.

Opportunity

1. Personalized and Precision Medicine:

Advances in genomics and biomarkers are paving the way for targeted heart failure therapies. Personalized medicine approaches can improve treatment efficacy and minimize adverse effects.

2. Emerging Markets:

Countries in Asia-Pacific, Latin America, and the Middle East are rapidly expanding their healthcare infrastructure and adopting new treatment paradigms, offering substantial growth opportunities for heart failure therapeutics.

Market by System Type Insights

Based on therapeutic class, the Angiotensin Receptor-Neprilysin Inhibitors (ARNIs) segment accounted for the largest share in 2023. This dominance is driven by the superior clinical efficacy of ARNIs in reducing cardiovascular mortality and heart failure-related hospitalizations. Additionally, the SGLT2 Inhibitors segment is expected to grow at the fastest pace due to recent regulatory approvals and their emerging role in both heart failure with preserved and reduced ejection fraction.

Market by End-Use Insights

The Hospital Pharmacies segment led the market in 2023, accounting for the largest revenue share. Hospitals remain the primary distribution channel due to the critical and acute nature of heart failure treatment, which often requires inpatient care and immediate therapeutic intervention. The Online Pharmacies segment is anticipated to witness robust growth, supported by increasing digital health adoption and the convenience of home delivery for chronic care drugs.

Market by Regional Insights

North America dominated the Global Heart Failure Therapeutics Market in 2023, owing to a high prevalence of heart failure, well-developed healthcare systems, and rapid adoption of advanced therapies. However, Asia-Pacific is poised to register the highest growth rate during the forecast period, driven by growing healthcare investments, rising disease awareness, and a large patient population.

Competitive Scenario

Key players in the Global Heart Failure Therapeutics Market include Novartis AG, AstraZeneca plc, Pfizer Inc., Merck & Co., Inc., Johnson & Johnson, Amgen Inc., Bristol-Myers Squibb Company, Bayer AG, Abbott Laboratories, and GlaxoSmithKline plc. These companies are focusing on expanding their cardiovascular portfolios through clinical trials, strategic collaborations, and regulatory approvals.

Key Developments:

In 2023, AstraZeneca received expanded FDA approval for dapagliflozin to treat heart failure with preserved ejection fraction (HFpEF).

In 2024, Novartis announced the launch of a new formulation of sacubitril/valsartan for improved patient compliance.

In 2025, Pfizer initiated clinical trials for a first-in-class gene therapy targeting advanced heart failure phenotypes.

Scope of Work – Global Heart Failure Therapeutics Market

FAQs

1) What is the current market size of the Global Heart Failure Therapeutics Market?

The Global Heart Failure Therapeutics Market was valued at USD 13.6 billion in 2023.

2) What is the major growth driver of the Global Heart Failure Therapeutics Market?

The rising prevalence of heart failure and continuous therapeutic innovation are the major growth drivers.

3) Which is the largest region during the forecast period in the Global Heart Failure Therapeutics Market?

North America held the largest market share in 2023, while Asia-Pacific is projected to experience the highest growth rate.

4) Which segment accounted for the largest market share in the Global Heart Failure Therapeutics Market?

The Angiotensin Receptor-Neprilysin Inhibitors (ARNIs) segment accounted for the largest share in 2023.

5) Who are the key market players in the Global Heart Failure Therapeutics Market?

Key players include Novartis AG, AstraZeneca plc, Pfizer Inc., Merck & Co., Johnson & Johnson, and Amgen Inc.